{{Rsnum
|rsid=4986910
|Gene=CYP3A4
|Chromosome=7
|position=99760901
|Orientation=minus
|ReferenceAllele=T
|MissenseAllele=C
|GMAF=0.003214
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP3A4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 0.0 | 3.7 | 96.3
| JPT | 0.0 | 0.9 | 99.1
| YRI | 0.0 | 0.0 | 0.0
| ASW | 0.0 | 1.8 | 98.2
| CHB | 0.0 | 3.7 | 96.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 2.0 | 98.0
| HapMapRevision=28
}}[[rs4986910]], also known as 1334T>C, 23171T>C or M445T, is a SNP in the [[CYP3A4]] gene.

The [[rs4986910]](C) allele defines the CYP3A4*3 variant.

{{PharmGKB
|RSID=rs4986910
|Name_s=CYP3A4*3, c.1334T>C, mRNA 1438T>C, p.Met445Thr; 445Thr allele, 1334 C allele
|Gene_s=CYP3A4, CYP3A, CYP3A5P2
|Feature=Exon/NonSyn, Intron, Intron
|Evidence=PubMed ID:12966368
|Annotation=Risk or phenotype-associated allele: CYP3A4*3 (rs4986910) 445Thr, 1334 C allele Phenotype: Two patients taking tacrolimus carried the CYP3A4*3 (445Thr) allele. The tacrolimus dose-adjusted C(0) in these 2 patients was higher than that in patients with the wild-type (455 Met/Met) genotype (n = 62), as follows: 134.9 (106.6-163.2) versus 83.83 (33.83-397.8) ng/mL per mg/kg, respectively. This difference was also observed at 12 months after transplantation, as follows: 147.3 (117.0-177.5) versus 88.79 (26.0-432.0) ng/mL per mg/kg. Study size: 64. Study population/ethnicity: Renal transplant recipients from the outpatient clinic of the Erasmus Medical Center in Rotterdam in the Netherlands, who had received a renal graft at least 1 year before the start of the study and were administered tacroliums (n = 64). Significance metric(s): Empirical evidence of too small numbers to analyze statistically. Type of association: GN; PK.
|Drugs=tacrolimus
|Drug Classes=
|Diseases=Organ Transplantation; Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165110656
}}

{{PMID Auto
|PMID=19214745
|Title=Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists
|OA=1
}}

{{PharmGKB
|RSID=rs4986910
|Name_s=CYP3A4:M445T; CYP3A4*3
|Gene_s=CYP3A4, CYP3A, CYP3A5P2
|Feature=Exon/NonSyn, Intron, Intron
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp3a4/haplotype.jsp#ImportantHaplotypeInformationforCYP3A4-21
|Annotation=Defining variant for CYP3A4*3; one of the first missense polymorphisms in CYP3A4.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145184
}}

{{PMID Auto
|PMID=17615053
|Title=Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk.
|OA=1
}}

{{PMID Auto
|PMID=19076156
|Title=Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
|OA=1
}}

{{GET Evidence
|gene=CYP3A4
|aa_change=Met445Thr
|aa_change_short=M445T
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4986910
|overall_frequency_n=61
|overall_frequency_d=10758
|overall_frequency=0.0056702
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|pph2_score=0.998
|nblosum100=2
|autoscore=3
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}